GlassScriptPhysician profile
Scott D Eriksen
NPI 1346611704
$8,339.80
in general payments reported to CMS, 2019-2025
34 companies · $671 in 2025
The $671 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,389 · 2022: $2,536 · 2023: $1,914 · 2024: $830 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,415.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $927.97 | 2021-2025 | |
| Esperion Therapeutics, INC. | $735.67 | 2021-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $724.64 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $695.07 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $519.29 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $515.28 | 2022-2025 | Cardiomems, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $470.27 | 2021-2025 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $451.06 | 2021-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.19 | 2021-2025 | Jardiance |
| Pfizer INC. | $362.13 | 2021-2024 | |
| Boston Scientific Corporation | $353.42 | 2021-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $341.26 | 2021-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $238.76 | 2023-2025 | Amvuttra, Onpattro |
| Amgen INC. | $216.37 | 2021-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $172.87 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $158.88 | 2021-2024 | Cleviprex, Kengreal |
| Cvrx, INC. | $137.53 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $115.98 | 2021-2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $115.66 | 2022 | |
| Amarin Pharma, INC. | $114.41 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $97.72 | 2022-2023 | Uptravi, Opsumit |
| Edwards Lifesciences Corporation | $87.30 | 2021 | |
| Medtronic, INC. | $80.77 | 2022 | |
| Irhythm Technologies, INC. | $55.07 | 2022-2023 | Zio Xt Patch |
| Mallinckrodt Hospital Products INC. | $47.52 | 2024-2025 | Acthar |
| Atricure, INC. | $44.69 | 2023 | |
| Astellas Pharma US INC | $30.97 | 2021-2022 | |
| Novo Nordisk INC | $21.87 | 2023 | Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $19.57 | 2024 | Arcalyst |
| Ucb, INC. | $19.35 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $15.88 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.13 | 2021 | |
| Scpharmaceuticals INC. | $13.25 | 2023 | |
| Philips North America LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Eriksen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.